Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1 Approval expands the Daxxify® label to include efficacy data over the 52-week ASPEN repeat dose clinical study. Daxxify® for cervical dystonia is the…Original Article
FDA Approves First Therapeutic Indication for Revance’s Daxxify (daxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
